Fintel reports that on January 5, 2024, Cantor Fitzgerald initiated coverage of Capricor Therapeutics (NasdaqCM:CAPR) with a Overweight recommendation.
Analyst Price Forecast Suggests 319.52% Upside
As of December 16, 2023, the average one-year price target for Capricor Therapeutics is 22.78. The forecasts range from a low of 12.12 to a high of $42.00. The average price target represents an increase of 319.52% from its latest reported closing price of 5.43.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Capricor Therapeutics is 122MM, an increase of 771.18%. The projected annual non-GAAP EPS is 0.36.
What is the Fund Sentiment?
There are 52 funds or institutions reporting positions in Capricor Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to CAPR is 0.01%, an increase of 415.08%. Total shares owned by institutions increased in the last three months by 103.12% to 5,859K shares. The put/call ratio of CAPR is 0.14, indicating a bullish outlook.
What are Other Shareholders Doing?
Highbridge Capital Management holds 2,790K shares representing 9.06% ownership of the company.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 767K shares representing 2.49% ownership of the company. No change in the last quarter.
VEXMX – Vanguard Extended Market Index Fund Investor Shares holds 341K shares representing 1.11% ownership of the company. In it’s prior filing, the firm reported owning 336K shares, representing an increase of 1.64%. The firm decreased its portfolio allocation in CAPR by 24.52% over the last quarter.
Geode Capital Management holds 269K shares representing 0.87% ownership of the company. In it’s prior filing, the firm reported owning 298K shares, representing a decrease of 11.05%. The firm decreased its portfolio allocation in CAPR by 34.68% over the last quarter.
FSMAX – Fidelity Extended Market Index Fund holds 137K shares representing 0.44% ownership of the company. In it’s prior filing, the firm reported owning 114K shares, representing an increase of 16.45%. The firm increased its portfolio allocation in CAPR by 55.13% over the last quarter.
Capricor Therapeutics Background Information
(This description is provided by the company.)
Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.